Global Antiplatelet Drugs Market
The Global Antiplatelet Drugs Market, by Drug Class (Phosphodiesterase Inhibitors & Thromboxane Inhibitors, Irreversible COX (Cyclooxygenase) Inhibitors, Adenosine Reuptake Inhibitors, Glycoprotein IIB/IIIA Inhibitors, and ADP (Adenosine Diphosphate) Receptor Inhibitors), by Mode of Administration (Intravenous and Oral), by Application (Interventions, Angioplasty, Arterial Thrombosis, Percutaneous Coronary, Myocardial Infarction, and Others), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa) had a market valuation of US$ 1.5 billion in 2017 and is estimated to grow at a CAGR of 7.6 percent during the forecast period (2018 – 2026).
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2190
In pathophysiological situations such as hypoxia, myocardial infarction, and strokes, antiplatelet treatment is deemed to be critical in avoiding abnormal platelet activation. Antiplatelet medicines lower the incidence of cardiovascular events by 20-25 percent in patients with existing Coronary Artery Disease (CAD) or at high risk of CAD, according to a 2007 research published in the Indian Journal of Pharm Science. In order to guard against undesired clot formation following initial platelet activation, manufacturers in the global antiplatelet drugs market target either surface receptors or enzymes in the platelet. As the risk of myocardial infarction, stroke, and mortality remains a chronic concern for people with cardiovascular disease, further research of novel antiplatelet treatments is necessary.
Browse 31 Market Data Tables and 33 Figures spread through 185 Pages and in-depth TOC on “Global Antiplatelet Drugs Market, by Drug Class (Phosphodiesterase Inhibitors & Thromboxane Inhibitors, Irreversible COX (Cyclooxygenase) Inhibitors, Adenosine Reuptake Inhibitors, Glycoprotein IIB/IIIA Inhibitors, and ADP (Adenosine Diphosphate) Receptor Inhibitors), by Mode of Administration (Intravenous and Oral), by Application (Interventions, Angioplasty, Arterial Thrombosis, Percutaneous Coronary, Myocardial Infarction, and Others), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa) – Global Forecast to 2026”
The cost of medications is another major element influencing illness treatment compliance, and it is also an important aspect of rational drug prescription. The pharmaceutical business offers numerous branded formulations of the same medication, each with a significant price variation. The majority of medications in India are branded, and the drugs recommended by clinicians may have a negative impact on the patient’s expenses. The gap in the highest and least price of the same medicine made by several pharmaceutical firms, as well as the percentage difference in cost per 10 tablets, were estimated in a research published in The International Journal of Basic & Clinical Pharmacology in 2016. Clopidogrel 150 mg tablet (148.7 percent), clopidogrel 75 mg (106.3 percent), clopidogrel 300 mg tablet (42.9 percent), aspirin 75 mg (51.5 percent), aspirin 150 mg (69.8 percent), prasugrel 5 mg (94.4 percent), prasugrel 10 mg (54.8 percent), and ticlopidine 250 mg (49.8 percent). Ticagrelor 90 mg has the lowest percent cost fluctuation (0 percent). Aspirin (75 mg) and clopidogrel (75 mg) had the largest price variation (235.6 percent) in combination treatment, followed by aspirin (150 mg) and clopidogrel (75 mg) (24.2 percent). As a result, there is a critical need for the production of low antiplatelet drugs with few adverse effects and high effectiveness.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/2190
Due to the rising incidence of cardiovascular illnesses, the global antiplatelet drugs market is anticipated to grow at a CAGR of 7.6 percent over the forecast period. As per the Centers for Disease Control and Prevention (CDC), about 40,000 children in the U.S. were conceived with coronary heart disease in 2016.
Due to the growing number of dental goods accessible in the market, the oral segment is projected to produce substantial revenue in 2018.
Key companies contributing in the global antiplatelet drugs market are Daiichi Sankyo, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Sanofi, The Medicines Company, AstraZeneca Plc., Otsuka Pharmaceutical Company, Ltd., Merck & Co., Inc., and Eli Lilly and Company.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027